- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02729337
Affecting the Epidemiology of HIV in Uganda
Affecting the Epidemiology of HIV in Uganda Through Older Adolescents
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators propose to develop a comprehensive, text messaging-based HIV prevention program for Ugandan adolescents 18-22 years of age. The guiding theoretical model is the Information-Motivation-Behavioral Skills (IMB) Model of HIV Preventive Behavior.
Intervention development will be iterative: In Phase 1, the investigators will identify an intervention content "map." Then, online focus groups (FG) will be conduct online with Ugandan young adults (n = 40-80) to confirm program components (e.g., social support via Text Buddy, optimal time of delivery of daily text messages) and saliency of intended program topics.
In Phase 2, the investigation team will "translate" content into a bank of text messages that will be reviewed for comprehensiveness and inclusion of the most pertinent topics. The final pool of messages among Ugandan young adults will be tested in the Content Advisory Council (CAC; n = 30) to assess their reactions to the content, scope, style, and tone of the messages.
In Phase 3, the investigators will merge the content with the software program developed to deliver the intervention and then internally conduct a functionality test of the programmed messages. Following, the protocol and program will be tested in a beta test of 20 Ugandan adults.
In Phase 4, the investigators will test the intervention in a randomized controlled trial of 200 Ugandan young adults randomly assigned to either the intervention (n = 100) or control (n = 100) arms. The main outcome measures will focus on feasibility (e.g., recruitment and retention rates) and acceptability (e.g., Text Buddy). The primary efficacy outcome measures, measured at 3-months post-intervention, will be: (a) frequency of unprotected sex acts; (b) sustained sexual abstinence, and (c) increased HIV testing rates.
Specific Aims are as follows:
Specific Aim 1: Design a 6-week text messaging-based HIV prevention and healthy sexuality program for adolescents 18-22 years old.
Specific Aim 2: Pilot test the intervention for feasibility and acceptability among 18- to 22-year-old Ugandans.
Specific Aim 3: Obtain preliminary data needed for a larger-scale controlled trial services study to examine program efficacy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Mbarara, Uganda
- Internet Solutions for Kids Uganda
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- living in Uganda
- aged 18-22 years
- able to read English
- exclusive owner of a cell phone
- using text messaging for at least 6 months
- intended to have the same phone number or the next six months
- able to access the Internet (to complete online surveys)
- able to provide informed consent
Exclusion Criteria:
- no other exclusion criteria will be applied
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ITG (In This Together)
This will be a multi-week behavioral intervention delivered daily via text messaging.
Content will be based upon the IMB model of HIV preventive behavior and informed by our formative work.
|
Comprehensive, mHealth-based HIV prevention program for Ugandan adolescents 18-22 years of age.
|
No Intervention: Control Group
Given the preliminary nature of the intervention development, the control group will be inactive but blinded.
They will receive two messages per week encouraging them to make healthy sexual decisions to reduce their HIV risk.
Messages will be didactic and not driven by the IMB model.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Program feasibility: Recruitment
Time Frame: 24 weeks
|
The number of participants recruited for the RCT (n=200)
|
24 weeks
|
Program feasibility: Retention
Time Frame: Through study completion, an average of 6 weeks
|
The number of participants that will remain in the study at program end (80%)
|
Through study completion, an average of 6 weeks
|
Program acceptability as assessed by a scale created for the RCT
Time Frame: At intervention end, 6-weeks post baseline
|
Participant ratings of program features (e.g., Text Buddy) at intervention end
|
At intervention end, 6-weeks post baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of participants reporting condom use during sex as assessed by self-report
Time Frame: At intervention end, 6-weeks post baseline
|
The percent of participants who report, at intervention end, using condoms during sex always versus not using condoms at least once, during the intervention period
|
At intervention end, 6-weeks post baseline
|
Percent of participants reporting abstinence as assessed by self-report
Time Frame: At intervention end, 6-weeks post baseline
|
The percent of participants who report, at intervention end, not having sex versus having sex at least once, during the intervention period
|
At intervention end, 6-weeks post baseline
|
Percent of participants who have gotten an HIV test as assessed by self-report
Time Frame: At intervention end, 6-weeks post baseline
|
The percent of participants who report, at intervention end, having gotten an HIV test versus not, during the intervention period
|
At intervention end, 6-weeks post baseline
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- MH109296
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on ITG (In This Together)
-
Stanford UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Active, not recruitingType 1 DiabetesUnited States
-
University of Illinois at ChicagoNational Institute on Minority Health and Health Disparities (NIMHD); UIC Center... and other collaboratorsRecruitingAttention Deficit Hyperactivity DisorderUnited States
-
University of NebraskaNational Institute of Nursing Research (NINR)CompletedCoronary Heart Disease | Cardiac RehabilitationUnited States
-
University of TorontoUniversity Health Network, Toronto; University of Western Ontario, Canada; Institute... and other collaboratorsCompletedStroke | Activities of Daily Living | Mobility Limitation | BalanceCanada
-
University of AlicanteEuropean CommissionCompleted
-
University of CopenhagenVelux FondenCompletedSensory Loss (Impairment of Sight and/or Hearing)Denmark
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); S...RecruitingObesity | Overweight | Body Weight | Weight Loss | Body Weight Changes | Chronic Disease | Overweight and Obesity | Physical Inactivity | Behavior, Eating | Weight ReductionUnited States
-
Beijing Tiantan HospitalRecruiting
-
Children's Hospital Medical Center, CincinnatiUniversity of Alabama at Birmingham; United States Department of DefenseRecruiting
-
Instituto do Cancer do Estado de São PauloCompletedPhenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53 (BREAST-TP53)Breast Cancer | Li-Fraumeni Syndrome | TP53 R337H | Prognosis Breast CancerBrazil